Federal prosecutors say an Orange County man ran a $270 million Medi-Cal drug scam and now faces a 30-year federal prison sentence after pleading guilty.
Story Snapshot
- Prosecutors say nearly $270 million in false Medi-Cal drug claims were submitted in 11 months.
- The defendant pleaded guilty to wire fraud tied to the scheme.
- Officials packaged the case within a larger health care fraud crackdown.
- The case echoes known Medicaid drug-fraud tactics that exploit complex billing rules.
What Prosecutors Say Happened
Federal officials charged that Paul Richard Randall and partners submitted nearly $270 million in false claims to California’s Medicaid program, known as Medi-Cal, over 11 months. The claims targeted pricey prescription drugs with generic ingredients. Prosecutors said many drugs were not medically needed and often were never provided to patients. Randall later pleaded guilty to one count of wire fraud tied to the scheme, according to the United States Department of Justice.
The United States Attorney’s Office described the matter as part of a broader push against health care fraud. Officials highlighted the scale, speed, and sophistication of the billing. They said the operation aimed at high-reimbursement medications and exploited weaknesses in the payment system. The Department of Justice listed the case among several taken on during a multi-jurisdiction enforcement drive, signaling a priority to deter similar fraud across programs.
The Guilty Plea and Maximum Exposure
Randall admitted to wire fraud in federal court, which carries a statutory maximum penalty of 30 years in prison when tied to certain health care contexts. Prosecutors linked the charge to the large volume of false submissions and the use of electronic communications to carry out the fraud. The plea followed earlier charges that outlined how the claims were prepared and routed for payment by Medi-Cal, California’s public health program for low-income residents.
Authorities said the scheme focused on medications that could draw higher payouts under program rules. That strategy amplified losses quickly. The Department of Justice placed this case in a published roundup of health care and pandemic-related fraud prosecutions. That packaging underscored a message that federal and state partners are stepping up audits, data analysis, and criminal charges to protect scarce public funds and patient care integrity.
Why This Case Hits a Nerve
Medicaid drug fraud drains money meant for vulnerable patients. It raises costs for taxpayers and adds pressure on honest doctors and pharmacists. Government watchdogs have long warned that drug diversion rings and complex billing tricks can overwhelm controls. The Government Accountability Office has documented how fraudsters exploit gaps like prior authorization changes, claim edits, and high-volume prescription patterns to move fast and avoid detection until losses mount.
An Orange County man was sentenced today to 360 months in federal prison for masterminding a massive health care fraud scheme in which nearly $270 million in fraudulent claims were submitted to Medi-Cal over an 11-month span for expensive prescription drugs containing generic… pic.twitter.com/NuCSciCJM8
— FBI Los Angeles (@FBILosAngeles) September 9, 2026
California’s Medi-Cal system has adjusted rules in the past to keep patient access to medicine, especially during program transitions. Those shifts can create short windows where bad actors test the system. State notices and federal summaries describe how prior authorization requirements and claim edits have been suspended and later reinstated in phases, reflecting a constant balance between access and oversight. Fraud cases like this show how even careful policy shifts can be targeted by scams.
What It Means Going Forward
Health care fraud cases often advertise large claim totals and maximum penalties. The totals reflect alleged or admitted false billings, not always the final loss or restitution. The sentencing process weighs guidelines, evidence, and cooperation. Still, the government’s focus is clear. Prosecutors are signaling that complex, pharmacy-focused schemes remain a top target. That matters to families on both sides of politics who see a system that too often rewards insiders while shortchanging patients.
Sources:
townhall.com, justice.gov, nationaltoday.com, cmadocs.org, medi-calrx.dhcs.ca.gov, gao.gov
